The family-owned pharma cautioned that early 2012 success doesn't mean the second half will be a breeze.
Sanofi is girding itself for an ugly year, forecasting a 12%-15% drop in business earnings per share for 2012 as the company absorbs the loss of patent exclusivity on a stable of drugs that brought in more than €4 billion last year.
Days after a $158 million settlement of charges that its Janssen unit fraudulently marketed Risperdal in Texas, Johnson & Johnson forecast fourth-quarter net earnings of just $218 million due to settlement costs and the recall of its DePuy ASR artificial hip.
Amgen's global sales, up 3% in the third quarter, met analyst estimates, but its new denosumab franchise reflected slower growth than expected.
Johnson & Johnson and Forest Labs both posted lower profit for the three months ended September 30.
AstraZeneca is reviewing its UK financial PR business amid media speculation on a possible acquisitions run in the US, reports our sister publication, PRWeek UK.
Pfizer may be headed toward a major restructuring that could include the sale of some of its most enduring brands, an analyst says.
Fourth quarter and full year earnings were posted by Merck and GSK today, and both companies suffered financial losses due to patent expiries, drug safety issues and ongoing litigation.
*Group discounts available on request
Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.